JPWO2021048821A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021048821A5 JPWO2021048821A5 JP2022516271A JP2022516271A JPWO2021048821A5 JP WO2021048821 A5 JPWO2021048821 A5 JP WO2021048821A5 JP 2022516271 A JP2022516271 A JP 2022516271A JP 2022516271 A JP2022516271 A JP 2022516271A JP WO2021048821 A5 JPWO2021048821 A5 JP WO2021048821A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- compound
- sleepiness
- subject
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 25
- 206010041349 Somnolence Diseases 0.000 claims 15
- 208000032140 Sleepiness Diseases 0.000 claims 13
- 230000037321 sleepiness Effects 0.000 claims 13
- 230000036470 plasma concentration Effects 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000004622 sleep time Effects 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 3
- 229940126062 Compound A Drugs 0.000 claims 2
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 2
- 208000033409 Narcolepsy type 2 Diseases 0.000 claims 2
- 238000011374 additional therapy Methods 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- UXZAJSZFFARTEI-GUMHCPJTSA-N methyl (2R,3S)-3-(methanesulfonamido)-2-[(4-phenylcyclohexyl)oxymethyl]piperidine-1-carboxylate Chemical compound COC(=O)N1CCC[C@H](NS(C)(=O)=O)[C@@H]1COC1CCC(CC1)c1ccccc1 UXZAJSZFFARTEI-GUMHCPJTSA-N 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- -1 (4-phenylcyclohexyl)oxy Chemical group 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000016588 Idiopathic hypersomnia Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 102000002512 Orexin Human genes 0.000 claims 1
- 206010062519 Poor quality sleep Diseases 0.000 claims 1
- 230000036626 alertness Effects 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 239000003874 central nervous system depressant Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960001340 histamine Drugs 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- UXZAJSZFFARTEI-UHFFFAOYSA-N methyl 3-(methanesulfonamido)-2-[(4-phenylcyclohexyl)oxymethyl]piperidine-1-carboxylate Chemical compound CS(=O)(=O)NC1C(N(CCC1)C(=O)OC)COC1CCC(CC1)C1=CC=CC=C1 UXZAJSZFFARTEI-UHFFFAOYSA-N 0.000 claims 1
- 208000001797 obstructive sleep apnea Diseases 0.000 claims 1
- 108060005714 orexin Proteins 0.000 claims 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 208000033914 shift work type circadian rhythm sleep disease Diseases 0.000 claims 1
- 239000000021 stimulant Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962900310P | 2019-09-13 | 2019-09-13 | |
| US62/900,310 | 2019-09-13 | ||
| US202063031687P | 2020-05-29 | 2020-05-29 | |
| US63/031,687 | 2020-05-29 | ||
| PCT/IB2020/058482 WO2021048821A1 (en) | 2019-09-13 | 2020-09-12 | Use of an orexin 2 receptor agonist for the treatment of excessive sleepiness |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022547604A JP2022547604A (ja) | 2022-11-14 |
| JP2022547604A5 JP2022547604A5 (https=) | 2023-09-20 |
| JPWO2021048821A5 true JPWO2021048821A5 (https=) | 2023-09-20 |
Family
ID=72521681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022516271A Pending JP2022547604A (ja) | 2019-09-13 | 2020-09-12 | 過度の眠気の治療のためのオレキシン２受容体アゴニストの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220331303A1 (https=) |
| EP (1) | EP4028003A1 (https=) |
| JP (1) | JP2022547604A (https=) |
| KR (1) | KR20220062361A (https=) |
| CN (1) | CN114555083A (https=) |
| AU (1) | AU2020347578A1 (https=) |
| BR (1) | BR112022004576A2 (https=) |
| CA (1) | CA3154320A1 (https=) |
| CO (1) | CO2022004589A2 (https=) |
| MX (1) | MX2022003017A (https=) |
| WO (1) | WO2021048821A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4065585B1 (en) | 2019-11-25 | 2025-08-20 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| AU2021205892B2 (en) | 2020-01-10 | 2026-04-23 | Takeda Pharmaceutical Company Limited | A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome P450 |
| CN116583502A (zh) | 2020-09-03 | 2023-08-11 | 欧瑞夏治疗有限公司 | 二环-杂环衍生物及其作为食欲素-2受体激动剂的用途 |
| US12006330B2 (en) | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| WO2024075825A1 (ja) | 2022-10-07 | 2024-04-11 | キッセイ薬品工業株式会社 | シクロペンタン化合物 |
| EP4719397A1 (en) * | 2023-06-02 | 2026-04-08 | Takeda Pharmaceutical Company Limited | Use of an orexin 2 receptor agonist for improving respiratory function during sleep |
| WO2025124698A1 (en) | 2023-12-12 | 2025-06-19 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
| TW202542165A (zh) | 2023-12-19 | 2025-11-01 | 瑞士商愛杜西亞製藥有限公司 | 大環食慾素激動劑 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0815134B1 (en) | 1995-03-14 | 2002-06-05 | Praecis Pharmaceuticals Incorporated | Modulators of amyloid aggregation |
| PT929574E (pt) | 1996-08-27 | 2005-11-30 | Praecis Pharm Inc | Moduladores da agregacao de peptidos beta-amiloides compreendendo d-aminoacidos |
| EP1196609A2 (en) | 1999-06-28 | 2002-04-17 | Oklahoma Medical Research Foundation | Catalytically active recombinant memapsin and methods of use thereof |
| LT3984994T (lt) * | 2016-02-04 | 2024-10-10 | Takeda Pharmaceutical Company Limited | Pakeistas piperidino junginys kaip 2 tipo oreksino agonistas narkolepsijai gydyti |
| JOP20190008A1 (ar) * | 2016-07-26 | 2019-01-24 | Purdue Pharma Lp | علاج ومنع اضطرابات النوم |
| AU2020346456A1 (en) * | 2019-09-13 | 2022-04-14 | Takeda Pharmaceutical Company Limited | TAK-925 for use in treating narcolepsy |
-
2020
- 2020-09-12 KR KR1020227011859A patent/KR20220062361A/ko active Pending
- 2020-09-12 BR BR112022004576A patent/BR112022004576A2/pt unknown
- 2020-09-12 CA CA3154320A patent/CA3154320A1/en active Pending
- 2020-09-12 AU AU2020347578A patent/AU2020347578A1/en not_active Abandoned
- 2020-09-12 CN CN202080072019.0A patent/CN114555083A/zh active Pending
- 2020-09-12 EP EP20772441.0A patent/EP4028003A1/en not_active Withdrawn
- 2020-09-12 WO PCT/IB2020/058482 patent/WO2021048821A1/en not_active Ceased
- 2020-09-12 JP JP2022516271A patent/JP2022547604A/ja active Pending
- 2020-09-12 US US17/642,337 patent/US20220331303A1/en not_active Abandoned
- 2020-09-12 MX MX2022003017A patent/MX2022003017A/es unknown
-
2022
- 2022-04-11 CO CONC2022/0004589A patent/CO2022004589A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stepnowsky Jr et al. | Nasal CPAP treatment for obstructive sleep apnea: developing a new perspective on dosing strategies and compliance | |
| JP6659072B2 (ja) | メラトニンアゴニスト治療 | |
| JP2023139000A (ja) | 睡眠時無呼吸を治療する方法及び組成物 | |
| Noda et al. | Continuous positive airway pressure improves daytime baroreflex sensitivity and nitric oxide production in patients with moderate to severe obstructive sleep apnea syndrome | |
| Martin et al. | Effect of ipratropium bromide treatment on oxygen saturation and sleep quality in COPD | |
| JP2022547711A (ja) | ナルコレプシーの治療に使用するためのｔａｋ－９２５ | |
| JP2021516218A (ja) | 睡眠時無呼吸を治療するための方法および組成物 | |
| US20220331303A1 (en) | Use of an orexin 2 receptor agonist for the treatment of excessive sleepiness | |
| JP2003503450A5 (https=) | ||
| HU216731B (hu) | Modafinil alkalmazása alvási apnoe és központi eredetű légzészavarok kezelésére szolgáló gyógyászati készítmény előállítására | |
| US20080261931A1 (en) | Method and Means of Preventing and Treating Sleep Disordered Breathing | |
| JPWO2021048821A5 (https=) | ||
| JP4896334B2 (ja) | 睡眠時呼吸障害を治療及び診断する方法並びにその方法を実施する手段 | |
| JP2021001221A (ja) | 精神障害の治療における使用のためのイロペリドン代謝物 | |
| CA3223121A1 (en) | Methods for treating obstructive sleep apnea | |
| AU2005212149B2 (en) | Method of treating and diagnosing sleep disordered breathing using zonisamide and means for carrying out the method | |
| WO2025232814A1 (zh) | 腺苷a2a受体拮抗剂在青光眼治疗及预防中的应用 | |
| JPWO2021048822A5 (https=) | ||
| AU2006201655B2 (en) | Use of agomelatine in obtaining medicaments intended for the treatment of bipolar disorders | |
| JPWO2021207054A5 (https=) | ||
| TW202502342A (zh) | 食慾素２受體促效劑用於改善睡眠期間之呼吸功能的用途 | |
| NZ760594B2 (en) | Methods and compositions for treating excessive sleepiness | |
| JP2007077149A (ja) | アゴメラチンと気分調整剤との新たな組み合わせ、及びそれを含有している医薬組成物 |